Table 2.

HDACs expression in experimental models of liver fibrosis.

Expression	HDAC	Experimental Model
Increased expression	HDAC1	Primary mouse HSCs [78], mouse CCl4-fibrosis [80]
	HDAC2	Primary mouse HSCs [78], mouse [80] and rat [81] CCl4-fibrosis, TGFβ-treated HSC-T6 [80] and LX2 cell lines [81], human fibrotic liver [80]
	HDAC8	Primary mouse HSCs [78], rat CCl4-fibrosis, TGFβ-treated LX2 cells [81]
	HDAC4	Rat CCl4-fibrosis [80,82], primary rat HSCs [82]
	HDAC5	Mouse CCl4-fibrosis [80]
	HDAC9	Mouse CCl4-fibrosis [80], human PBC/alcoholic cirrhosis [83]
	HDAC6	Mouse [80] and rat [81] CCl4-fibrosis, TGFβ-treated LX2 cells [81]
	SIRT2	Human fibrotic liver tissues [106]
	HDAC11	Mouse CCl4-fibrosis [80]
Decreased expression	HDAC9	Primary mouse HSCs [79]
	HDAC10	Primary mouse HSCs [79]
	SIRT1	Primary mouse [90,93] and rat [92] HSCs, TGFβ-treated LX2 cells [90,91], mouse [90,93,94] and rat [92] CCl4-fibrosis, mouse TAA-fibrosis [93], mouse ethanol-fibrosis [95], rat BDL-fibrosis [96,97], NAFLD patients [98]
	SIRT3	Primary rat HSCs [108] and rat CCl4-fibrosis [108]
	SIRT4	Human fibrotic liver tissues [113]
	SIRT6	Human cirrhotic liver tissues [115] and primary mouse HSCs [115]